Latest Conference Articles

February 23rd 2021, 10:00pm

DONNA Foundation Marathon Weekend

A cancer diagnosis often comes with concerns of what’s next for patients. One concern is how they’re going to afford their treatments. Here, a panel of experts discuss what options are available.

February 23rd 2021, 7:00pm

DONNA Foundation Marathon Weekend

There are two myths that patients with cancer believe when it comes to being health advocates. Here, a panel of experts look to dispel those myths to help patients become better advocates.

February 23rd 2021, 2:00pm

ASCO Genitourinary Symposium

Positive results from the phase 3 CLEAR clinical trial, presented at the 2021 ASCO Genitourinary Cancers Symposium, are just one more dataset that could offer “a sense of hope and promise” for patients with advanced renal cell carcinoma (RCC), says the study’s lead author, Dr. Robert J. Motzer.

February 19th 2021, 10:00pm

DONNA Foundation Marathon Weekend

There are several health equity barriers in patients with cancer, one of which involves adequate access to clinical trials. Here, a panel of experts and a cancer survivor discuss ways to improve access.

February 18th 2021, 2:00pm

ASCO Genitourinary Symposium

The study results, according to one expert, show that Cabometyx should be considered the new standard for systemic therapy in patients with metastatic papillary renal cell carcinoma.

February 15th 2021, 10:00pm

ASCO Genitourinary Symposium

Treatment with Padcev, compared to chemotherapy, continues to show better results in patients with advanced urothelial carcinoma who had previously received certain therapies.

February 13th 2021, 10:00pm

ASCO Genitourinary Symposium

The results of the phase 3 trial, according to one expert, support the use of Lenvima with Keytruda as a possible first-line treatment option for patients with advanced renal cell carcinoma.

February 13th 2021, 6:00pm

ASCO Genitourinary Symposium

Treatment with sapanisertib was associated with limited activity and poor safety outcomes in patients with refractory metastatic renal cell carcinoma.

February 13th 2021, 4:00pm

ASCO Genitourinary Symposium

For patients to maintain or improve their quality of life through their cancer treatment, it is pivotal that they communicate with their health care team.

February 12th 2021, 10:20pm

ASCO Genitourinary Symposium

Clinical trials remain the gold standard when it comes to finding new treatment options for patients, particularly when it comes to renal cell carcinoma. But even if the results are positive and this combination proves to be beneficial, patients should still discuss all of their options with their oncologist to find the right sequence of treatment, says one expert.